Skip to content
Screener

Charles River Laboratories CRL EPS (Diluted)

EPS (Diluted) at other companies

Labcorp Holdings logo
Labcorp HoldingsLH
$3.64+28.2%
Rapid Micro Biosystems logo
Rapid Micro BiosystemsRPID
-$0.31-19.2%
Sotera Health logo
Sotera HealthSHC
$0.19+533%
Fortrea Holdings Inc. logo
Fortrea Holdings Inc.FTRE
-$0.14+96.6%
Revvity logo
RevvityRVTY
$0.36+2.9%
IQVIA logo
IQVIAIQV
$1.53-0.6%

Other financials

Income statement

See full
Revenue$1.0B-2.7%
Gross profit$349.0M-3.5%
Operating income$119.9M+19.7%
Net income-$1.5M-103%

Balance sheet

See full
Cash & equivalents$240.6M+30.2%
Total debt$3.0B+8.1%
Total equity$2.8B-15.3%
Total assets$7.5B-0.4%

Cash flow

See full
Operating cash flow$179.7M-12.2%
CapEx$31.1M-11.9%
Free cash flow$148.6M-12.2%

Valuation

See full
Market cap$12.56B+70.1%
Enterprise value$15.36B+53.4%
P/S3.1×+1.3×

Profitability

See full
Gross margin84.7%—
Operating margin13%-2.4pp
Net margin-6%—
FCF margin9.3%-5.1pp

Returns & leverage

See full
Return on equity-7.7%—
Debt / equity1.1×+0.2×
Current ratio1.3×0.0×

Where this comes from

Reported directly by Charles River Laboratories in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: Charles River Laboratories’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 9:21 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001100682-26-000118
Line itemThree Months Ended / June 27, 2026Three Months Ended / June 28, 2025Six Months Ended / June 27, 2026Six Months Ended / June 28, 2025
Net income (loss) attributable to common shareholders$(1,482)$52,326$(16,325)$77,795
Earnings (loss) per common share
Basic$(0.03)$1.06$(0.34)$1.56
Diluted$(0.03)$1.06$(0.34)$1.55
Weighted-average number of common shares outstanding
Basic48,02149,14948,48649,913
Diluted48,02149,31648,48650,089
See Notes to Unaudited Condensed Consolidated Financial Statements.

Item 1. Financial Statements

FAQ

What is Charles River Laboratories's EPS (diluted)?
Charles River Laboratories (CRL) reported EPS (diluted) of -$0.03 in Q2 2026.
How has Charles River Laboratories's EPS (diluted) changed year-over-year?
Charles River Laboratories's EPS (diluted) decreased by 102.8% year-over-year, from $1.06 to -$0.03.
What is the long-term trend for Charles River Laboratories's EPS (diluted)?
Over 3 years (2021 to 2025), Charles River Laboratories's EPS (diluted) has grown at a -27.5% compound annual growth rate (CAGR), from $7.60 to -$2.90.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Charles River Laboratories's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude